This phase III trial conducted in China randomized 501 patients with stage II-III NSCLC (AJCC v 9) to platinum-based doublet chemotherapy plus the PD-L1 antibody toripalimab (202 participants) or placebo (202 participants) group. This evidence concerns the gene CD274 and non-small cell lung carcinoma.